BM
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation is a seed to Series C stage investment firm. It has made 45 investments. 33% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $66.8M (across 43 rounds with reported amounts).
Portfolio
45
Fund Size
—
Top Stage
Series A
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
52 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Owlstone Medical | Series E | $27M | Jan 2025 |
 Freya Biosciences | Series A | — | Nov 2024 |
| 55Metis, Inc. | Series A | $5.5M | Sep 2024 |
 Kanvas Biosciences | Series A | $12.5M | Jul 2024 |
 Ethris | Unknown | $5M | Jun 2024 |
 Pula | Series B | $20M | Apr 2024 |
 Vedanta Biosciences | Series D | $40M | Jan 2024 |
| SStellapps Technologies | Series C | $26M | Jan 2024 |
 Bactolife | Series A | — | Aug 2023 |
 Aphea.bio | Series C | — | Jul 2023 |
 MyDawa | Seed | $1.5M | Jan 2023 |
| Aphea.bio | Series C | — | Jan 2023 |
 Eleven Therapeutics | Seed | $22M | Aug 2022 |
 Enko | Series C | $70M | Jul 2022 |
 SwipeRx | Series B | $27M | Jan 2022 |
| AAdjuvant | Unknown | $300M | Feb 2021 |
 Adjuvant Capital | Unknown | $300M | Feb 2021 |
 Redwing Labs | Seed | $1M | Jan 2021 |
 Apeel Sciences | Series E | $990M | Jan 2021 |
| Enko | Series B | $45M | Jun 2020 |
 Immunocore | Series B | $140M | Apr 2020 |
 C16 Biosciences | Series A | — | Mar 2020 |
| SSure Chill | Unknown | — | Jul 2019 |
| LLyndra Therapeutics Inc. | Series B | $55M | Jan 2019 |
| Apeel Sciences | Growth | $70M | Aug 2018 |
Page 1 of 3
Top Co-Investors
Gates Foundation13 shared
Polaris Partners7 shared
Alexandria Venture Investments5 shared
Omega Funds4 shared
Merck3 shared
British International Investment3 shared
Horizons Ventures3 shared
Endeavor3 shared
Lux Capital3 shared
Germin8 Ventures3 shared
Learn Capital3 shared
Flagship Pioneering3 shared
Gilead Sciences2 shared
Hopu Investments2 shared
The Invus Group, LLC2 shared
Y Combinator2 shared
ARCH Venture Partners2 shared
Viking Global Investors2 shared
Andreessen Horowitz2 shared
Last updated: 20 October 2026